The historical rank and industry rank for vTv Therapeutics's FCF Margin % or its related term are showing as below:
VTVT'
s FCF Margin % Range Over the Past 10 Years
Min: -15332.3 Med: -815.16 Max: -28.27
Current: -28.27
During the past 13 years, the highest FCF Margin % of vTv Therapeutics was -28.27%. The lowest was -15332.30%. And the median was -815.16%.
VTVT's FCF Margin % is ranked better than 60.38% of 959
companies
in the Biotechnology industry
Industry Median: -84.65
vs VTVT: -28.27
vTv Therapeutics FCF Margin % Related Terms
vTv Therapeutics FCF Margin % Historical Data
* Premium members only.
The historical data trend for vTv Therapeutics's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, vTv Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
vTv Therapeutics FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, vTv Therapeutics's FCF Margin % distribution charts can be found below:
* The bar in red indicates where vTv Therapeutics's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
vTv Therapeutics (VTVT) has a FCF Margin % of 24.85% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on vTv Therapeutics and its competitors. According to the industry distribution chart, vTv Therapeutics ranks #380 out of 959 companies in the Biotechnology industry, placing it in the top 39.6%.
Is vTv Therapeutics' FCF Margin % too high?
vTv Therapeutics' current FCF Margin % is 24.85%. Based on the distribution chart, vTv Therapeutics ranks #380 out of 959 companies in the Biotechnology industry, which is above the industry midpoint. Overall, vTv Therapeutics has a GF Score™ of 35/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does vTv Therapeutics' FCF Margin % compare to CRDF and GUTS?
According to the Biotechnology industry distribution chart, vTv Therapeutics ranks #380 out of 959 companies for FCF Margin %. This puts vTv Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on vTv Therapeutics and its competitors. vTv Therapeutics's current FCF Margin % is 24.85%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is vTv Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, vTv Therapeutics (VTVT) is currently considered Significantly Undervalued. The stock's GF Value™ is $7,827.31, compared to a current price of $37.80 — trading 99.5% below its estimated fair value. The current FCF Margin % is 24.85%. vTv Therapeutics' overall GF Score™ is 35/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For vTv Therapeutics (VTVT), the current FCF Margin % is 24.85% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is vTv Therapeutics (VTVT) Overvalued in 2026?
Based on GuruFocus' analysis, vTv Therapeutics stock appears to be undervalued.
The current stock price of $37.80 is trading 99.5% below its estimated GF Value™ of $7,827.31.
GuruFocus considers vTv Therapeutics to be Significantly Undervalued.
Key valuation signals for VTVT:
FCF Margin %: 24.85%
GF Value™: $7,827.31 vs. price of $37.80 (99.5% below fair value)
No single metric tells the full story. See the VTVT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.
35GF Score
Get the complete analysis for VTVT
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VTVT has been successfully added to your 
